ACUMEN PHARMACEUTICALS INC (ABOS)
US00509G2093 - Common Stock
ACUMEN PHARMACEUTICALS INC
NASDAQ:ABOS (1/14/2025, 8:21:39 PM)
Premarket: 1.51 -0.05 (-3.21%)1.56
-0.03 (-1.89%)
Company Profile
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 51 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer’s pathology). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The firm is developing sabirnetug for intravenous (IV), administration every four weeks for the treatment of early AD.
Company Info
ACUMEN PHARMACEUTICALS INC
427 Park St.
Charlottesville VIRGINIA
P: 19253688508
CEO: Daniel O'Connell
Employees: 52
Website: https://acumenpharm.com/
ABOS News
6 days ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings6 days ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety FindingsPhase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of...
2 months ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference2 months ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a...
2 months ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights2 months ago - Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business HighlightsExpect ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first...
ABOS Twits
Here you can normally see the latest stock twits on ABOS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
